skip to main content

Gadolinium Group II Safety CKD — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

EasyChronic Kidney DiseaseGadolinium Group II Safety CKDESENeph

A 55-year-old man with CKD G4 is referred for an MRCP to investigate bile duct obstruction. The radiologist asks about gadolinium safety at eGFR 20. What group of gadolinium agents is recommended?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Group II macrocyclic agents (Gadobutrol, Gadoterate meglumine, Gadoteridol) are recommended – they have the lowest NSF risk even in severe CKD; Group I linear agents should be avoided below eGFR 30

The risk of nephrogenic systemic fibrosis (NSF) varies dramatically between gadolinium agents. Group II agents (macrocyclic: Gadobutrol [Gadovist], Gadoterate meglumine [Dotarem], Gadoteridol [ProHance]) have very high thermodynamic stability, extremely low NSF risk, and can be used in CKD G4-5 with appropriate clinical indication. Group I agents (linear: Gadodiamide [Omniscan], Gadopentetate [Magnevist]) have been associated with nearly all NSF cases and should be avoided in eGFR <30. ESUR and ACR guidelines provide clear risk stratification.

Reference: ESUR 2018 – Gadolinium Guidelines; ACR 2022 – Contrast Manual